TCL Archive Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint March 29, 2013
TCL Archive Contract Authority Expiration Confuses NCI Money Bill Estimates, Which Range From $605 To $650 Million June 21, 1974